Houlihan Lokey reports fiscal Q4 2026 results on May 6 with one dominant theme: the Street remains constructive, but has spent months quietly lowering the bar.
Options positioning tells an unusually bullish story for an earnings approach. The put/call ratio is running at 0.10 — a full standard deviation below its 20-day average of 0.18. Call demand is swamping puts, keeping the PCR near its 52-week floor of 0.097. That's a rare alignment of options sentiment with a stock that's already down 3.1% on the week and 11% year-to-date. Investors are not reaching for downside protection here; they're betting on a bounce.
The analyst backdrop is decidedly more cautious than the options market implies. Every bellwether name that touched HLI in the recent cycle trimmed their target. Morgan Stanley cut to $193 from $205 in early April, maintaining Overweight. Goldman Sachs lowered to $184 from $210 on April 1, while preserving its Buy. These cuts leave the Street mean target at $174.50 — roughly 14% above the current $153.08 close — which looks generous relative to where targets were being set before the macro sell-off began. Bulls point to last quarter's 17.9% revenue growth and a 93.8% gross margin as evidence the business model is firing. Bears note that the stock traded as high as the low $200s less than six months ago, that the co-chairman sold $8 million in shares last August, and that advisory backlogs are acutely sensitive to deal-flow conditions that remain choppy in 2026.
The earnings history adds a note of caution that the options market appears to be ignoring. The most recent print, in late January, saw HLI fall roughly 6% the following day and extend losses to nearly 7% over the next five sessions. That was a single data point, but it was a clean post-result sell-off in a market that was not especially stressed at the time. Short interest at 2.4% of free float is modest and has actually trimmed 4% over the past week, while borrow costs at 0.3% are low and availability remains abundant — there is no short-side pressure building ahead of Wednesday.
The print will therefore test whether a genuine re-acceleration in M&A advisory activity can justify paying a 17.5x trailing earnings multiple for a business whose stock is already well off its highs — and whether call-heavy options positioning proves prescient or premature.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
